昭衍新藥(603127.SH)擬推2022年A股員工持股計劃 籌資總額上限為494.388萬元
格隆匯8月15日丨昭衍新藥(603127.SH)公佈2022年A股員工持股計劃(草案),該員工持股計劃的股份來源為公司回購專用賬户回購的A股股份。此次員工持股計劃經公司股東大會審議通過之後,擬通過非交易過户等法律法規允許的受讓方式受讓公司回購的A股股票,股票總數不超過12.40萬股,約佔公司目前股本總額的0.023%。擬籌集資金總額上限為494.388萬元,以“份”作為認購單位,每份份額
為1元,認購份額不超過494.388萬份,具體份額根據實際出資繳款金額確定。
該員工持股計劃購買回購股票的價格為該員工持股計劃草案公吿前1個交易日公司股票交易均價的50%,即39.87元/股。
該員工持股計劃的參與對象為公司監事、高級管理人員、核心技術(業務)骨幹。參加該員工持股計劃的總人數不超過20人,其中監事、高級管理人員為4人,具體參加人數根據員工實際繳款情況確定。
該員工持股計劃的存續期為48個月,自公司公吿最後一筆標的股票過户至該員工持股計劃名下之日起算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.